ReviewFrontiers in immunology2020
Sarcoidosis Epidemiology: Race Matters.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 135 citations in OpenAlex.
- Proof-of-concept PET imaging of pulmonary sarcoidosis using VAP-1-targeted radiotracer [Respiratory research · 2025Trial
- Pulmonary Sarcoidosis in Qatar: Clinical Features, Diagnostic Profile and Treatment Patterns in a Multi-Ethnic Population.The clinical respiratory journal · 2026Observational
- Quality of Life in Sarcoidosis.Diagnostics (Basel, Switzerland) · 2026Review
- Diagnostic challenges in isolated cardiac sarcoidosis.ESC heart failure · 2026Review
- Incidence and risk factors of postoperative visual loss in cardiac surgery in the United States from the national inpatient sample 2013 to 2022.Journal of cardiothoracic surgery · 2026Article
- A case of trigeminal nerve neurosarcoidosis initially presenting with isolated neurological findings mimicking trigeminal schwannoma: a case report and review of the literature.Journal of medical case reports · 2026Review
- Characterizing Race-Based Differences in Antisynthetase Syndrome Interstitial Lung Disease.Biomedicines · 2026Article
- Article
- Cardiovascular Manifestations and Immunobiology of Sarcoidosis.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Uncovering Sex and Gender Differences in Sarcoidosis: A Systematic Review of Current Evidence.Journal of personalized medicine · 2026Review
- Asthma in Patients With Confirmed Pulmonary Sarcoidosis.Canadian respiratory journal · 2026Review
- Contemporary management of sarcoidosis.Frontiers in medicine · 2026Review
- Sarcoidosis and Risk of Nephrolithiasis in US Black Women: Data from the Black Women's Health Study.CHEST pulmonary · 2025Article
- Racial, Ethnic, Sex, and Gender Equity for Inclusive Interstitial Lung Disease Research: An Official American Thoracic Society Research Statement.American journal of respiratory and critical care medicine · 2025Review
- Neurosarcoidosis: a review from diagnosis and future perspectives.EClinicalMedicine · 2025Review
- The Mirage of Individualized Therapy in the United States: Barriers in Pulmonary Hypertension Due to Sickle Cell Disease and Sarcoidosis.American journal of respiratory and critical care medicine · 2025Article
- Exploring gender and ethnic disparities in sarcoidosis: insights from the British Thoracic Society UK Interstitial Lung Disease Registry.BMJ open respiratory research · 2025Article
- Clinical and Demographic Characteristics of Oral Sarcoidosis: A Systematic Review of Case Reports and Case Series.Journal of clinical medicine · 2025Review
- Use of 18F-FDG PET in assessing response to treatment in adults with pulmonary sarcoidosis: A systematic literature review.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Extracellular vesicles in sarcoidosis: unlocking molecular signatures for precision therapy.ERJ open research · 2025Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rather than a single disease entity, sarcoidosis may be a constellation of "sarcoidoses" with a characteristic pattern of organ involvement and clinic course, depending upon the triggering exposure and underlying epidemiologic factors such as race. This review examines the racial disparities inherent to sarcoidosis disease course and mortality and discusses factors that may be responsible for these findings. In the United States, black patients with sarcoidosis experience more severe pulmonary disease, more multiorgan involvement, and an overall worse prognosis with higher rates of hospitalization and mortality. Beyond inherent genotype, ascertainment and access to medical care, physician implicit bias, and patient perceived discrimination likely play a role. Moving forward, epidemiologic concepts can be used to formulate strategies for control, treatment, and even prevention of disease in black Americans at risk for developing life-altering or life-threatening sarcoidosis phenotypes. Identification and rectification of modifiable risk factors such as socioeconomic status, lack of insurance, and financial barriers to care as well as the incorporation of implicit bias training for physician will likely lead to improvement in discordant outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.